TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax-Reference-Cited by-同舟云学术

TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax

Published:2023-11-25 Issue:1 Volume:38 Page:82-95
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Tyagi Anudishi,Jaggupilli Appalaraju,Ly Stanley,Yuan Bin,El-Dana Fouad,Hegde Venkatesh L.,Anand Vivek,Kumar Bijender,Puppala Mamta,Yin Zheng,Wong Stephen T. C.^ORCID,Mollard Alexis,Vankayalapati Hariprasad^ORCID,Foulks Jason M.,Warner Steven L.,Daver Naval^ORCID,Borthakur Gautam^ORCID,Battula V. Lokesh^ORCID

Funder

Dainippon Sumitomo Pharma

UT | University of Texas MD Anderson Cancer Center

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-023-02086-6.pdf

Reference52 articles.

1. Carow CE, Levenstein M, Kaufmann SH, Chen J, Amin S, Rockwell P, et al. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood. 1996;87:1089–96.

2. Bolouri H, Farrar JE, Triche T Jr, Ries RE, Lim EL, Alonzo TA, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2018;24:103–12.

3. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid Leukemia. N Engl J Med. 2016;374:2209–21.

4. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100:1532–42.

5. Yanada M, Matsuo K, Suzuki T, Kiyoi H, Naoe T. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia. 2005;19:1345–9.